Navigation Links
Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial
Date:5/28/2008

- Company to Host Conference Call/Webcast at 8:30 a.m. EDT on May 29 -

SOMERSET, N.J., May 28 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL) today announced that the preliminary statistical analysis of data from its confirmatory Phase IIIb clinical trial of its lead compound, ONCONASE (ranpirnase), did not meet statistical significance for the primary endpoint of survival in unresectable malignant mesothelioma (UMM). However, a statistically significant improvement in survival was seen in the treatment of UMM patients who failed one prior chemotherapy regimen. Alfacell plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the treatment of this patient population, which represents a currently unmet medical need.

The preliminary results are based on 320 evaluable events that occurred in the clinical trial out of a total of 428 patients randomized. The trial was designed to show a statistically significant improvement in overall survival (p < 0.048) for UMM patients who were treated with a combination of ONCONASE plus doxorubicin as compared to patients who were treated with doxorubicin as a single agent. The analysis of the data did not show a statistically significant improvement for evaluable patients receiving ONCONASE plus doxorubicin (unadjusted log rank p=0.80). The median survival time (MST) for evaluable patients who received ONCONASE plus doxorubicin was 11.1 months as compared to 10.7 months for patients who received doxorubicin as a single agent.

Statistically significant results were achieved in evaluable UMM patients (N=122) who failed a prior chemotherapy regimen before entering this clinical trial. Patients who received ONCONASE plus doxorubicin expe
'/>"/>

SOURCE Alfacell Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Alfacells ONCONASE(R) Shows Potential as Radiation Sensitizer for Lung Cancer Treatment
2. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
3. Alfacell Reports Financial Results for First Quarter of Fiscal 2008
4. Alfacell Corporation to Present at UBS Global Life Sciences Conference
5. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
6. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
7. Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation
8. Dr. Peter Nash, Ph.D. Joins Mach One Corporation as Chief Scientist
9. Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
10. NanoBio Corporation Completes Interim Analysis of Phase 2 Clinical Trial in Onychomycosis
11. NanoBio Corporation Successfully Completes Phase 2b Study in Herpes Labialis

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...K,Calif.,Nov.25/PRNewswire/--PraxisElectronicMedic...ademyofFamilyPhysicians,(AAFP)FamilyPracticeManage...medicalquality,healthmaintenance,anddiseasemanagem...salsoranked#1amongdoctorsindicatingtheirEMRhadapos...alsorankednumberoneinthecountryinprovidingexcellen...
(Date:11/25/2009)...HIA,Nov.25/PRNewswire-FirstCall/--ERT(Nasdaq: ERES...ny,sPresidentandCEO,andKeithSchneck,theCompany,sEx...the21stAnnualPiperJaffrayHealthCareConferenceat1:3... Interestedpartiesmayaccessthepresentationbyvisiti...m .Thewebcastmayalsobeaccessedat http://www.corpor...
(Date:11/25/2009)...RK,Md.,Nov.25/PRNewswire-USNewswire/--RemediumTech...oamthatstopsseverebleeding,wonfirstprizeand$10,000...ecurityChallenge2009,companyofficialsannouncetoday...eworld,Remedium,steampitchedtheirinventionattheGSC...iness. ,, Remedium( www.remediumtechnologies.co...
Breaking Medicine Technology:Praxis EMR Wins Top Rankings in 2009 AAFP EHR User Satisfaction Survey 2ERT to Present at the 21st Annual Piper Jaffray Health Care Conference on December 1, 2009 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 3Key to evolutionary fitness 3A Cut the calories 9078 1Key to evolutionary fitness 3A Cut the calories 9078 2First step to converting solar energy using artificial leaf 12859 1First step to converting solar energy using artificial leaf 12859 2Specialized California Medical Center 28Heart411 com 29 Offers Top Notch Cardiothoracic Surgery 50474 1Specialized California Medical Center 28Heart411 com 29 Offers Top Notch Cardiothoracic Surgery 50474 2
... Md., April 27 As body mass increases, so does ... according to Baltimore researchers. A new study, ...f the American Urological Association (AUA), asses...luated insurance claims of 95,962 subjects over a ...ify whether obesity is associated with a UTI diagn...
... Build on Pivotal Phase III Study for the Treatmen...., April 27 Ferring Pharmaceuticals announced tod...garelix for injection, a new injectable gonadotrop...proved by the U.S. Food and Drug Administration (F...d prostate cancer. The announcement was made at...
Other Medicine Technology:Obesity Associated With Higher Risk for Urinary Tract Infections 2Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy 2Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy 3Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy 4Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy 5
(Date:11/27/2009)...rael,Nov.27/PRNewswire-FirstCall/--ShamirOpticalIn...iderofinnovativeproductsandtechnologytotheophthalm...haddeclaredadividenddistributioninanaggregateamoun...ntheNovember25,2009representativerateofexchange),o...heNovember25,2009representativerateofexchange)pero...
(Date:11/27/2009)... Voyant Health™ announced today that Spectr...s TraumaCad Enterprise orthopedic templating solut... (PRWEB) November 27, 2009...trum Health (Grand Rapids, Michigan) has licensed ...ution and its TraumaCad Extend workflow solution, ...
(Date:11/26/2009)...ov.27/PRNewswire/--ThediabetespopulationintheUnite...medicalspendingonthediseaseisprojectedtohit$336bil...shedintheDecemberissueof DiabetesCare .TheNational...voNordisk,commissionedtheanalysisbyateamfromtheUni...numberofAmericanslivingwithdiabeteswillrisefrom23....
(Date:11/26/2009)... No more letters from the North Pole, Textsanta.n...ages from Santa , North P...ional efficiencies at the North Pole Santa Claus h...all over the globe informed of his Christmas progr...research department have identified a large and gr...
(Date:11/25/2009)...25/PRNewswire-USNewswire/--Whenmostpeopleheartheac...analsogivepatientsthehelptheyneed.TMJstandsfortheT...le)contacts/connectswithyourskull(temporalbone). ,...tionarepainwithchewing,clickingorpoppingofthejaw.B...cluding:headaches,fatigue,sleepdisturbances,irrita...
Breaking Medicine News(10 mins):Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 3Health News:Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes 2
...A study conducted by researchers from the Royal De...s are to be blamed if babies are born short. //Mot...come. The study is still in progress. But the ...ot seem to be on the plumper side. Conversely, ba...
...An outbreak of Norovirus has been reported in Roya...ulted in the complete closure of wards 4,5,27 // a...rmed that the virus has been contained in the ward...to visit patients in the hospital as a precautiona...
...Those in their 50s and 60s who want to lose weight... instead of counting calories, suggests new resear...and those who exercised lost a significant amount ...ned their strength and muscle mass and increased a...
...While kidney failure is a serious condition that r...bset of these patients are prone to developing ano... Fibrosis or Nephrogenic Fibrosing Dermopathy (NSF...ness and difficulty bending joints. In many cases,...
...Depressed older adults being treated in primary ca...than with antidepressant medicines, suggests a new...dults with depression have the best response when ...ew recommends this integrated approach instead of ...
...A new mechanism has been identified by scientists ...Vienna Biocenter in Austria that is involved in no... most important molecule for the control of cancer...any types of cancer. A report on the team's findin...
Other Medicine News:Health News:New Study Weighs Benefits of Exercise, Diets 2Health News:Dermatologists Provide Unique Evidence of Possible Cause of Rare Skin Condition 2Health News:Depressed Seniors in Primary Care Benefit Most From Team Approach 2Health News:Regulatory Mechanism for Tumor Suppressor Protein Identified 2Health News:Regulatory Mechanism for Tumor Suppressor Protein Identified 3
Babcock Grasper
...scopic Instruments incorporate a layered design un... and monitored to prevent stray electrosurgical bu...sulation failure or capacitive coupling; a well-do...d built into all AEM Instruments provides a neutra...
...scopic Instruments incorporate a layered design un... and monitored to prevent stray electrosurgical bu...sulation failure or capacitive coupling; a well-do...d built into all AEM Instruments provides a neutra...
...scopic Instruments incorporate a layered design un... and monitored to prevent stray electrosurgical bu...sulation failure or capacitive coupling; a well-do...d built into all AEM Instruments provides a neutra...
Medicine Products: